NDAVAGINALOINTMENT
Approved
Feb 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VAGISTAT-1 is a vaginal ointment containing tioconazole, an azole antifungal agent used to treat vaginal yeast infections (vulvovaginal candidiasis). It works by disrupting fungal cell membrane synthesis, killing the causative Candida organisms. This is an over-the-counter product for symptomatic relief in non-pregnant women.
LOE Approaching
As a mature OTC product approaching loss of exclusivity, the brand team is likely small and focused on defensive market retention and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VAGISTAT-1 is a defensive, execution-focused role suited to professionals skilled in brand stewardship, generic transition planning, and cost optimization. Career growth is limited by the product's mature LOE-approaching status; opportunities lie in managing decline and protecting market share rather than driving expansion.
Brand Manager (OTC)Product Manager
Worked on VAGISTAT-1 at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.